Thursday - May 1, 2025

LOGIN  |  REGISTER
Amneal Pharmaceuticals

Neogen® Launches New Assays for Histamine Detection

May 31, 2023 | Last Trade: US$5.01 0.04 -0.79

LANSING, Mich., May 31, 2023 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that it has launched two new assays for the detection of histamine, Reveal® for Histamine and Reveal Q+ for Histamine.

Reveal and Reveal Q+ assays are easy-to-use lateral flow tests that utilize a simple water extraction method, providing results in a matter of minutes and eliminating the need to dispose of any chemicals, as is needed with other commercially available histamine detection methods, reducing testing time.

"These two new tests are an excellent addition to our portfolio of food safety testing solutions, helping keep consumers safe and healthy," said John Adent, Neogen's President and CEO. "These rapid tests make it easy for producers and distributors to test for this toxin, backed by Neogen's reputation for providing accurate and reliable results."

  • Reveal for Histamine (PN 9548) is a qualitative lateral flow assay intended for visual screening of histamine at 50 parts-per-million (ppm) in scombroid species of fish, such as tuna and mahi-mahi.
  • Reveal Q+ for Histamine (PN 9549) is a quantitative lateral flow assay designed to be read on Neogen's Raptor® Integrated Analysis Platform. The assay provides quantitative results for histamine in scombroid species of fish and dry animal protein.

High levels of histamine may develop in fish species as they decompose, and the ingestion of histamine can cause scombroid poisoning in humans. Because of the potential for human illness, the U.S. Food and Drug Administration (FDA) has set an action level of 50 parts per million (PPM) for histamine in domestic and imported fish.

Neogen offers a comprehensive range of food safety diagnostic test products for foodborne bacteria, mycotoxins, food allergens, and other concerns. Its full line of mycotoxin test kits detects aflatoxin, deoxynivalenol (DON), fumonisin, ochratoxin, T-2/HT-2, and zearalenone.

About Neogen

Neogen Corporation develops and markets comprehensive solutions dedicated to food and animal safety, operating with the intention to "Every day, protect the people and animals we care about." The Company's Food Safety segment markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases, and sanitation concerns. Neogen's Animal Safety segment is a leader in the development of genomic solutions along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care, and disinfectants, as well as rodent and insect control solutions.

Media Contact 

Mary Gadola, Senior Product Manager, Immunodiagnostics and Natural Toxins
800.234.5333 ext. 2289, MGadola@Neogen.com

Recursion

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page